Xbrane Biopharma (Sweden) and Helvetic BioPharma (Switzerland) have signed a sales and distribution agreement to debut Xbrane's biosimilar medicine, Xlucane (Ranibizuma), in Iran. Xlucane is a biosimilar version of Lucentis for the treatment of age-related muscular degeneration. Xbrane estimates the market size for wet AMD in Iran comprises approximately 70,000 patients and constitutes a leading cause of blindness in the country.